The Liver Meeting 2025

The LIVE-SMART trial presented at AASLD 2025 shows that lactulose and Tai chi may prevent falls in individuals with cirrhosis and portal hypertension.

The post hoc subgroup analysis of the phase III MITIGATE trial shows the benefit of the humanized monoclonal anti-CD19 antibody inebilizumab in adults with IgG4-related disease (IgG4-RD) with pancreas, bile duct, and liver involvement at baseline.